Residual disease-guided strategy combining ibrutinib and venetoclax for the treatment of relapsed or refractory chronic lymphocytic leukemia

被引：0
|
作者：
Stocker, Nicolas
机构：
来源：
HEMATOLOGIE | 2022年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 175
页数：2
相关论文
共 50 条
  • [21] MINIMAL RESIDUAL DISEASE (MRD)-DRIVEN TREATMENT PERSONALIZATION WITH SEQUENTIAL ADDITION OF IBRUTINIB (IBR) TO VENETOCLAX (VEN) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE IMPROVE STUDY
    Scarfo, L.
    Heltai, S.
    Albi, E.
    Scarano, E.
    Schiattone, L.
    Farina, L.
    Gaidano, G.
    Deodato, M.
    Ferrario, A.
    Motta, M.
    Reda, G.
    Sancetta, R.
    Coscia, M.
    Ladetto, M.
    Laurenti, L.
    Varettoni, M.
    Perotta, E.
    Capasso, A.
    Ranghetti, P.
    Colia, M.
    Ghia, P.
    HAEMATOLOGICA, 2021, 106 (10) : 4 - 4
  • [22] Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
    Kater, Arnon P.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    van der Kevie-Kersemaekers, Anne-Marie F.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Brieghel, Christian
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Niemann, Carsten U.
    LANCET ONCOLOGY, 2022, 23 (06): : 818 - 828
  • [23] Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography
    Benedetti, Edoardo
    Barate, Claudia
    Bruno, Benedetto
    Bramanti, Emilia
    Ghia, Paolo
    Scarfo, Lydia
    Morganti, Riccardo
    Ricchiuto, Vittorio
    Galimberti, Sara
    LEUKEMIA RESEARCH, 2021, 100
  • [24] Venetoclax Management and care for patients with relapsed or refractory chronic lymphocytic leukemia
    Paradis, Heather Brumbaugh
    Alter, Debbie
    Lterandi, Diane
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (05) : 604 - 610
  • [25] The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia
    Brown, Jennifer R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 110 - 118
  • [26] Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Veliz, Marays
    Pinilla-Ibarz, Javier
    CANCER CONTROL, 2012, 19 (01) : 37 - 53
  • [27] BUDGETARY IMPACT OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Brito Filho, C.
    Vitale, V.
    Vieira, F. M.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [28] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study (vol 37, pg 2722, 2019)
    Hillmen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) : 1644 - 1644
  • [29] Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib
    Jones, Jeffrey
    Choi, Michael Y.
    Mato, Anthony R.
    Furman, Richard R.
    Davids, Matthew S.
    Heffner, Leonard T.
    Cheson, Bruce D.
    Lamanna, Nicole
    Barr, Paul M.
    Eradat, Herbert
    Halwani, Ahmad
    Chyla, Brenda
    Zhu, Ming
    Verdugo, Maria
    Humerickhouse, Rod A.
    Potluri, Jalaja
    Wierda, William G.
    Coutre, Steven E.
    BLOOD, 2016, 128 (22)
  • [30] IBRUTINIB TREATMENT IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: A CASE REPORT
    Malkan, U. Yavuz
    Gunes, G.
    Okay, M.
    Aksu, S.
    Sayinalp, N.
    LEUKEMIA RESEARCH, 2016, 49 : S38 - S38
12345